You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ)與艾德生物簽訂分子檢測與伴隨診斷戰略合作框架協議及相關附屬協議
格隆匯 12-25 21:25

格隆匯 12 月 25日丨廣生堂(300436.SZ)公佈,2020年12月24日,公司與廈門艾德生物醫藥科技股份有限公司(“艾德生物”)簽訂了《分子檢測與伴隨診斷戰略合作框架協議》(“戰略合作協議”)及相關附屬協議,雙方就公司抗腫瘤新藥GST-HG161不同腫瘤適應症的臨牀研究提供樣本檢測服務及伴隨診斷展開合作。

公司抗腫瘤新藥GST-HG161擬用於治療c-MET陽性肝細胞癌、非小細胞肺癌、胃癌等惡性腫瘤,目前正在進行I期劑量遞增階段臨牀試驗,並已爬坡至900mg劑量組。公司已着手準備GST-HG161項目的Ib/II期臨牀試驗,計劃於2021年第一季度正式啟動Ib/II期臨牀試驗。

戰略合作協議的簽訂,有助於雙方充分發揮各自在腫瘤治療創新藥物研發、基因檢測領域的專業優勢,共同推進GST-HG161的臨牀研究和MET伴隨診斷試劑盒的研發,對未來推動GST-HG161的伴隨診斷具有重要意義,將可能為多個腫瘤的精準治療提供全球領先的科學解決方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account